HMP Global December 10, 2025
In the health plan year 2025, health care stakeholders faced the lingering effects of the COVID-19 pandemic, a change in presidential and congressional party leadership, and artificial intelligence (AI)’s growing integration in health care. In addition, the rapid growth of the GLP-1 drug category overshadowed the impact of biologic-based products, especially cancer therapeutics.
These market factors focused the attention of business leadership, human resource departments (HR), and company boardrooms beyond health care costs. Such dynamic changes in this marketplace—shifts in regulation or law and economic ramifications—require a more robust understanding of roles, responsibilities, and available time for all business sector leaders to sustain their business through 2025 into 2026.
This column will review health care...







